BridgeMD
Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality
EU CTIS ID: 2022-502187-20-00
What this study is testing
To evaluate the effect of standard medical treatment (SMT) plus PE-A 5% (SMT+PE-A 5%) on 90-day overall survival
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female cirrhotic subjects between 18 and 79 years of age.
- Subjects with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization (must be ACLF-1b, -2, or -3a within the Screening Period [a maximum of 10 days])
- Willing and able to provide written informed consent or have an authorized representative able to provide written informed consent on behalf of the subject in accordance with local law and institutional policy
- In case of hepatic encephalopathy, informed consent will be provided by a relative or a legally authorized representative if the subject is considered incompetent to consent.
You likely can't join if
- Subjects without ACLF
- Subjects with severe thrombocytopenia (≤20×109/L) (based on local laboratory assessment)
- Subjects with chronic renal failure and currently receiving hemodialysis
- Evidence of current locally advanced or metastatic malignancy. Subjects with hepatocellular carcinoma within the Milan criteria (1 nodule ≤5 cm or 3 nodules ≤3 cm, non-melanocytic skin cancer, and controlled breast or prostate cancer can be included)
- Subjects with severe chronic heart failure (New York Heart Association [NYHA] class III or IV
- Subjects with severe pulmonary disease (Global Obstructive Lung Disease [GOLD] stage III or IV)
See the full eligibility criteria
Who can join
- Male or female cirrhotic subjects between 18 and 79 years of age.
- Subjects with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization (must be ACLF-1b, -2, or -3a within the Screening Period [a maximum of 10 days])
- Willing and able to provide written informed consent or have an authorized representative able to provide written informed consent on behalf of the subject in accordance with local law and institutional policy
- In case of hepatic encephalopathy, informed consent will be provided by a relative or a legally authorized representative if the subject is considered incompetent to consent.
What rules you out
- Subjects without ACLF
- Subjects with severe thrombocytopenia (≤20×109/L) (based on local laboratory assessment)
- Subjects with chronic renal failure and currently receiving hemodialysis
- Evidence of current locally advanced or metastatic malignancy. Subjects with hepatocellular carcinoma within the Milan criteria (1 nodule ≤5 cm or 3 nodules ≤3 cm, non-melanocytic skin cancer, and controlled breast or prostate cancer can be included)
- Subjects with severe chronic heart failure (New York Heart Association [NYHA] class III or IV
- Subjects with severe pulmonary disease (Global Obstructive Lung Disease [GOLD] stage III or IV)
- Subjects with severe myopathy as defined clinically
- Subjects with a known infection with human immunodeficiency virus (HIV) or have clinical signs and symptoms consistent with current HIV infection
- Females who are pregnant, breastfeeding, or if of childbearing potential, unwilling to practice a highly effective method of contraception (oral, injectable, or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, condom, or occlusive cap with spermicidal foam/gel/cream/suppository, male sterilization, or true abstinence*) throughout the study. * True abstinence: When this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods], declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception)
- Subjects with previous liver transplantation.
- Subjects receiving anti-platelet or anti-coagulant therapy (low molecular weight heparin [LMWH] for deep vein thrombosis [DVT] prophylaxis is allowed)
- Subjects with ACLF-1a or ACLF-3b after the Screening Period
- Participation in another clinical study within at least 30 days prior to screening
- Subjects with active drug addiction (exceptions: active alcoholism or marijuana)
- Subjects with a do-not-resuscitate order
- In the opinion of the investigator, the subject may have compliance problems with the protocol and the procedures of the protocol
- Subjects with current infection of COVID19, those who are less than 14 days post recovery or those who have clinical signs and symptoms consistent with COVID19 infection.
- Subjects fulfilling inclusion criteria that improve to no ACLF or to ACLF-1a or worsen to ACLF-3b during the Screening Period (between initial evaluation and time of randomization)
- Subjects with ACLF for more than 10 days prior to randomization
- Subjects with acute or subacute liver failure without underlying cirrhosis
- Subjects with septic shock requiring use of norepinephrine (> 0.3 mcg/kg/min) or need for a second vasopressor (including terlipressin)
- Subjects with active bacterial or fungal infection: who have received less than 24h of appropriate antibiotic treatment
- Subjects with severe respiratory failure with PaO2/FiO2 ≤200
- Subjects with active or recent bleeding (unless controlled for >48 hours)
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.